FreedomWorks Originals provides you entertainment and education to help you better understand economics, the workings of government, and our insight into the most important debates facing our nation today. Watch and subscribe today!
Back in May, a group of bipartisan lawmakers used a variety of misleading talking points to attack the Federal Communications Commission (FCC). The group, led by Senate Armed Services Committee Chairman Jim Inhofe (R-Okla.), took issue with the FCC’s order freeing up spectrum for use to develop next generation technology. The concerns revolved around objections by the Department of Defense (DoD) about whether this new allocation of spectrum would impact their ability to track aircraft.
On Friday, President Trump issued three executive orders (and threatened a fourth) outlining sweeping changes he planned to make regarding prescription drug prices in the United States. One order seeks to make federal grants to federally qualified health centers contingent upon discounted insulin prices. A second would allow personal and wholesale importation of prescription drugs from overseas. The third implements rebate reform for pharmacy benefits managers (PBMs).
Prices for prescription drugs in the U.S. are far too high. There is no denying this sad reality. According to an analysis done by the House Ways and Means Committee, the U.S. pays roughly four times as much as 11 similar nations for prescription drugs. For millions of patients, families, and caregivers, this is unacceptable. Policymakers are right when they say something needs to be done.
LIVE @WhiteHouse: Federal Affairs @DanielSavickas Assesses President @realDonaldTrump's Successful Deregulatory Agenda Before the Election! #ampFW https://t.co/1wJIGkdO4z https://t.co/QwzOQufZt9 pic.twitter.com/oGY617rzXE
FreedomWorks Foundation’s Regulatory Action Center (RAC) is driving comments in support of the Trump administration’s proposed changes bolstering restrictions on frivolous asylum claims. You can make your voice heard HERE.
WASHINGTON, D.C. -- In response to the Food and Drug Administration (FDA) authorizing Philip Morris to market its IQOS heating system as a modified risk tobacco product (MRTP), Dan Savickas, FreedomWorks Foundation’s Regulatory Policy Manager commented:
The Executive Branch of our federal government is massive; so massive that no one knows exactly how many federal agencies there are. Nevertheless, the Executive Office of the President (EOP) must efficiently manage the massive amount of regulatory actions that come from these innumerable agencies. Tasked with being the primary check-point for regulations before they are implemented, the Office of Information and Regulatory Affairs, otherwise known as OIRA, is the most important federal agency that you’ve probably never heard of.
FreedomWorks Foundation's Regulatory Action Center (RAC) has published an issue brief on the environmental regulations the Trump administration has rolled back. You can read the paper excerpted below or in its entirety in the attachment at the bottom of this post or HERE.